Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | SCN4A | P35499 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3456532 | 0.87 | MMP8 (0.43) | L3MBTL1SMN1; SMN2LMNAHSD17B10GAA | |
| SCHEMBL17497672 | 0.79 | SLC1A1 (0.54) | CYP2C19SMN1; SMN2TACR1 | |
| SCHEMBL17497668 | 0.79 | SLC1A1 (0.54) | CYP2C19SMN1; SMN2TACR1 | |
| SCHEMBL19305351 | 0.79 | SLC1A1 (0.54) | CYP2C19SMN1; SMN2TACR1 | |
| SCHEMBL21049648 | 0.77 | CYP2C19 (0.49) | CYP2C19SMN1; SMN2ALDH1A1LMNAHSD17B10 | |
| SCHEMBL31304908 | 0.74 | CYP2C19 (0.46) | CYP2C19SMN1; SMN2ALDH1A1LMNAHSD17B10 | |
| Methyl Alcohol SCHEMBL28310472 | 0.74 | SCN4A (0.47) | L3MBTL1SMN1; SMN2SCN4AALDH1A1LMNA | |
| SCHEMBL2016945 | 0.73 | CYP2C19 (0.52) | CYP2C19SMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL27795423 | 0.72 | LMNA (0.48) | L3MBTL1CYP2C19SMN1; SMN2LMNA | |
| SCHEMBL27141737 | 0.71 | CHRM1 (0.56) | L3MBTL1CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601251-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2014-11-12 | — | — | EP | disclosed |
| EP-2266946-A2 | Compound For The Treatment Of Metabolic Disorders | Wellstat Therapeutics Corporation (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-1601251-A4 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1601251-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2005-12-07 | — | — | EP | disclosed |
| WO-2004073611-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2004-09-02 | — | — | WO | disclosed |